Rhophylac and RhoGAM Are Equivalent Anti-D Products
Yes, Rhophylac and RhoGAM are both anti-D immune globulin products that can be used interchangeably for preventing Rh alloimmunization. 1
Key Clinical Points
They Are Therapeutically Equivalent
Both products contain Rh(D) immune globulin (RhIg) and serve the same clinical purpose: preventing RhD alloimmunization in RhD-negative individuals. The 2024 SMFM guidelines explicitly state that when a typically used brand of RhIg (such as RhoGAM or WinRho SDF) is not available, an equivalent RhIg product like Rhophylac may be substituted 1.
Important Differences to Consider
While therapeutically equivalent, there are practical differences:
Route of administration: Rhophylac can be given both intramuscularly (IM) or intravenously (IV), whereas RhoGAM is traditionally given IM only 2
Dosing: Both products contain 300 mcg (1500 IU) in standard preparations 2
Pharmacokinetics: When given IM, anti-D IgG concentrations differ between IV and IM routes for the first 7 days, but from 2-3 weeks onward, serum concentrations are comparable regardless of administration route 3, 4
Clinical Context: Supply Shortages
This question has become particularly relevant because in 2023 and 2024, manufacturers of RhoGAM and WinRho SDF reported supply reductions 1. During shortages, the SMFM recommends:
- Substituting with available equivalent products (HyperRHO S/D, Rhophylac)
- Prioritizing postpartum patients and antenatal patients at later gestational ages for available doses
Practical Administration Guidance
For IM administration: If large doses (>5 mL) are required and IM injection is chosen, administer in divided doses at different sites. Ensure the injection site allows reaching the muscle—consider IV administration if this is uncertain 2.
Do not administer subcutaneously into fatty tissue, as this may affect absorption 2.
Bottom Line for Practice
You can confidently substitute Rhophylac for RhoGAM (or vice versa) when one is unavailable. The choice between products should be based on availability, preferred route of administration (if Rhophylac's IV option is advantageous), and institutional formulary considerations. Both products are equally effective at preventing the devastating consequences of RhD alloimmunization, including hemolytic disease of the fetus and newborn 1.